Introduction
A medical device FTO analysis conducted using EPO claim scope assumptions will produce a different blocking risk picture from the same analysis conducted using Swiss Federal Patent Court claim construction standards. The difference is not marginal. The FPC applies a claim interpretation methodology that draws on both Swiss patent law and EPO practice — but reaches different conclusions from pure EPO prosecution-based scope in specific and commercially significant ways.
For medical device companies entering the Swiss market, the FTO that reflects what Swiss courts will actually decide about blocking risk is the one built on FPC claim construction — not on EPO claim scope assumptions applied to Swiss-validated European patents. The two analyses may agree on most blocking patents. On the patents that matter most — the ones closest to the product design, with prosecution histories that have narrowed their claims, or where equivalents analysis would expand or contract the blocking scope — they will often reach different conclusions.
Our analysis of FTO for pharmaceutical products in Switzerland covering SPC extensions and domestic patents covers the two-layer structure of Swiss patent FTO. This article covers the third dimension that pharma and medtech FTO both share: how the FPC’s claim construction approach determines what each blocking patent actually covers in Swiss enforcement proceedings, and how that determination affects both the blocking risk assessment and the design-around options available before launch.
The Swiss Federal Patent Court: Structure and Jurisdiction
FPC as the exclusive first-instance court: The Swiss Federal Patent Court (FPC), established in 2012, is the exclusive first-instance court for patent infringement and validity disputes in Switzerland. Unlike most European jurisdictions where patent cases are heard by general commercial courts with specialist chambers, Switzerland’s FPC is a dedicated patent court with permanent technical judges who have scientific and engineering expertise alongside legal qualification. This technical bench structure means that claim construction in FPC proceedings involves judges who can engage with the technical content of the patent without the level of expert testimony required in generalist commercial courts. The Swiss Federal Patent Court (FPC), established in 2012, is the exclusive first-instance court for patent infringement and validity disputes in Switzerland. Unlike most European jurisdictions where patent cases are heard by general commercial courts with specialist chambers, Switzerland’s FPC is a dedicated patent court with permanent technical judges who have scientific and engineering expertise alongside legal qualification. This technical bench structure means that claim construction in FPC proceedings involves judges who can engage with the technical content of the patent without the level of expert testimony required in generalist commercial courts.
The expedited proceedings option and its FTO implications: The FPC offers expedited proceedings for cases where the parties agree to a compressed schedule. Expedited FPC proceedings can resolve infringement disputes within 12 to 18 months of filing — significantly faster than main proceedings in most European jurisdictions. For FTO strategy, this compression matters: a patentee who chooses the FPC expedited track can obtain a first-instance infringement determination within the product’s first commercial year. The risk of a rapid expedited proceeding is a relevant input to the FTO risk assessment for medical devices entering the Swiss market, particularly where the potential blocking patent holder is an active litigant.
The FPC’s expedited nullity proceedings are covered in our analysis of the Swiss Federal Patent Court’s expedited nullity proceedings and their implications for pharma and medtech IP portfolios. Nullity proceedings at the FPC are the primary mechanism for challenging the validity of a blocking patent — and for medical device FTO, the availability of expedited nullity is a commercially significant option when a blocking patent has validity vulnerabilities that a conventional infringement defence could exploit.
How the FPC Approaches Claim Construction
The purposive construction standard: Swiss patent law applies a purposive construction approach to claim interpretation — meaning that claims are read in light of the patent’s description and drawings to give them their full technical meaning, not their broadest literal reading or a narrowing that would make the invention commercially valueless. The FPC’s purposive construction is functionally similar to the approach taken by the EPO Boards of Appeal in opposition proceedings but is applied in an enforcement context rather than a prosecution context. In practice, FPC claim construction produces claim scope that is neither as broad as a patentee might assert nor as narrow as an alleged infringer might prefer, calibrated to what a skilled person would understand the invention to cover given the specification and claims as a whole.
How prosecution history is used in FPC claim interpretation: The FPC uses the prosecution history — the communications between the applicant and the EPO during examination — as an interpretive tool for understanding the intended scope of the granted claims, but does not apply strict file wrapper estoppel in the US sense. Statements made during EPO prosecution that explicitly distinguished prior art and narrowed claim scope will inform FPC claim interpretation but do not create the absolute estoppel that US prosecution history creates under US claim construction doctrine. For FTO purposes, this means that prosecution history narrows FPC claim scope in a softer way than US file wrapper estoppel — it is an input to interpretation, not a hard boundary.
Equivalents: the FPC’s approach: The FPC applies a doctrine of equivalents under Article 66 of the Swiss Patent Act. An element that does not literally satisfy a claim element may still infringe if it performs essentially the same function in essentially the same way to achieve essentially the same result as the claimed element, and if a person skilled in the art would recognise this equivalence without inventive effort. The FPC’s equivalents doctrine is broadly comparable to the EPO’s approach in infringement-related contexts but is applied with attention to what the prosecution history reveals about the scope the applicant intended to claim. Where the prosecution history shows that the applicant deliberately narrowed a claim to overcome an objection, the FPC will not extend equivalents coverage to the element that was surrendered during prosecution.
“The FPC’s claim construction is not the same as EPO prosecution-based scope, and it is not the same as Swiss literal claim reading either. It is a purposive construction that uses the specification, the prosecution history, and the equivalents doctrine together to determine what the patent actually covers in Swiss enforcement — which may be broader or narrower than what the claim language suggests on its face.”
What FPC Claim Construction Means for Medical Device FTO
Why EPO prosecution-based scope assumptions can overstate blocking risk: A medical device FTO that assesses Swiss blocking risk using EPO prosecution-based claim scope — treating the claims as they were interpreted during EPO examination — may overstate blocking risk for patents where the prosecution history has narrowed the effective scope below the literal claim language. Where an EPO applicant made statements during prosecution that distinguished prior art by emphasising specific structural or functional limitations, those statements inform FPC claim interpretation in a way that reduces the effective blocking scope below what the granted claim language alone might suggest. An FTO that reads only the granted claims without reviewing the prosecution history may identify false blocking patents that the FPC would not find to infringe.
Where prosecution history estoppel narrows claims: For medical device patents with complex prosecution histories — particularly those involving multiple examination rounds, divisional applications, or inter partes oppositions at the EPO — the prosecution history is a substantial body of interpretive material. Claim elements that were added or narrowed during prosecution to distinguish specific prior art configurations are interpreted more restrictively by the FPC than their literal language might suggest. For FTO purposes, identifying these narrowed claim elements and assessing whether the product design falls outside the prosecution-narrowed scope — even if it would fall within the literal claim language — can reveal non-infringement positions that a literal claim analysis would miss.
How equivalents assessment changes design-around options: The FPC’s equivalents doctrine can work in both directions for medical device FTO. Where a product design avoids literal infringement of a blocking claim but achieves the same function by essentially the same means, the FPC may find infringement by equivalents. For design-around analysis, this means that a design modification that avoids the literal claim element must also be assessed against the equivalents standard — a modification that technically avoids literal infringement but uses a means that a skilled person would immediately recognise as equivalent may not provide genuine clearance in FPC proceedings. Conversely, where the prosecution history shows that the applicant surrendered coverage of a specific alternative during prosecution, that alternative may be outside the equivalents scope as well as the literal scope.
Preliminary Injunctions at the FPC: Speed and Standards
The FPC preliminary injunction timeline: The FPC can issue preliminary injunctions in medtech and pharma cases on a timeline that is relevant to commercial launch planning. Emergency ex parte preliminary injunction applications can be heard within days of filing where the urgency is established. Inter partes preliminary injunction proceedings — where the defendant has an opportunity to respond before the injunction is granted — typically resolve within 4 to 8 weeks of the application. For a medical device company launching in Switzerland, this timeline means that a patentee can seek and obtain preliminary injunctive relief before the product has established significant commercial traction.
The urgency requirement: Swiss preliminary injunction law requires the applicant to demonstrate urgency — that the harm cannot be remediated through subsequent damages if the product is allowed to remain on market during main proceedings. In practice, Swiss courts recognise the commercial urgency of patent infringement in market exclusivity contexts without requiring exceptional evidence of irreparable harm. For medical devices where the patentee has established market presence and the product launch represents a direct competitive threat, urgency is typically not a significant barrier to preliminary injunction applications at the FPC.
How Our FTO Service Covers Medical Device Clearance in Switzerland
Our freedom to operate service covers Swiss medical device FTO with claim scope assessment under FPC claim construction standards — purposive construction informed by the prosecution history, equivalents assessment under Article 66 of the Swiss Patent Act, and identification of prosecution history-narrowed claim elements that reduce effective blocking scope below the literal claim language. For each high-priority blocking patent, we provide a dual-layer analysis: literal claim infringement assessment under FPC purposive construction, and equivalents assessment for design-around alternatives that avoid literal infringement. The FTO output distinguishes between patents that are genuinely blocking under FPC standards and patents that appear blocking on a literal claim reading but are narrowed by their prosecution history to a scope that does not cover the product design. This distinction gives medical device product teams and their Swiss IP counsel a clearance assessment that reflects what FPC proceedings would actually determine, not what EPO prosecution-based scope suggests.
Swiss medical device FTO requires claim assessment under FPC purposive construction — not EPO prosecution-based scope. Our service covers prosecution history analysis, equivalents assessment under Swiss law, and design-around option evaluation calibrated to FPC standards. → Contact Us
Conclusion: The Takeaway
The Swiss Federal Patent Court’s claim construction approach — purposive construction informed by prosecution history, with a doctrine of equivalents applied under the Article 66 standard — produces blocking risk assessments that differ from EPO prosecution-based scope in ways that are commercially significant for medical device FTO. Patents that appear broadly blocking on a literal claim reading may be narrowed by their prosecution history to a scope that does not cover the product design. Design-around alternatives that avoid literal infringement may still be caught by equivalents analysis. And the FPC’s compressed preliminary injunction timeline makes early, accurate FTO clearance more important than in jurisdictions where enforcement proceedings take longer.
The medical device FTO that reflects actual Swiss enforcement risk is the one built on FPC claim construction standards — not on EPO assumptions applied to Swiss-validated patents. The gap between the two assessments is where the most consequential FTO errors in Swiss medical device market entry are made.
